Cargando…

A Synbiotic Formulation Comprising Bacillus subtilis DSM 32315 and L-Alanyl-L-Glutamine Improves Intestinal Butyrate Levels and Lipid Metabolism in Healthy Humans

The gut microbiota is a crucial modulator of health effects elicited by food components, with SCFA (short chain fatty acids), especially butyrate, acting as important mediators thereof. We therefore developed a nutritional synbiotic composition targeted at shifting microbiome composition and activit...

Descripción completa

Detalles Bibliográficos
Autores principales: tom Dieck, Heike, Schön, Christiane, Wagner, Tanja, Pankoke, Helga Carola, Fluegel, Monika, Speckmann, Bodo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747176/
https://www.ncbi.nlm.nih.gov/pubmed/35011015
http://dx.doi.org/10.3390/nu14010143
_version_ 1784630769150328832
author tom Dieck, Heike
Schön, Christiane
Wagner, Tanja
Pankoke, Helga Carola
Fluegel, Monika
Speckmann, Bodo
author_facet tom Dieck, Heike
Schön, Christiane
Wagner, Tanja
Pankoke, Helga Carola
Fluegel, Monika
Speckmann, Bodo
author_sort tom Dieck, Heike
collection PubMed
description The gut microbiota is a crucial modulator of health effects elicited by food components, with SCFA (short chain fatty acids), especially butyrate, acting as important mediators thereof. We therefore developed a nutritional synbiotic composition targeted at shifting microbiome composition and activity towards butyrate production. An intestinal screening model was applied to identify probiotic Bacillus strains plus various amino acids and peptides with suitable effects on microbial butyrate producers and levels. A pilot study was performed to test if the synbiotic formulation could improve fecal butyrate levels in healthy humans. A combination of Bacillus subtilis DSM (Number of German Collection of Microorganisms and Cell Cultures) 32315 plus L-alanyl-L-glutamine resulted in distinctly increased levels of butyrate and butyrate-producing taxa (Clostridium group XIVa, e.g., Faecalibacterium prausnitzii), both in vitro and in humans. Moreover, circulating lipid parameters (LDL-, and total cholesterol and LDL/HDL cholesterol ratio) were significantly decreased and further metabolic effects such as glucose-modulation were observed. Fasting levels of PYY (Peptide YY) and GLP-1 (Glucagon-like Peptide 1) were significantly reduced. In conclusion, our study indicates that this synbiotic composition may provide an effective and safe tool for stimulation of intestinal butyrate production with effects on e.g., lipid and glucose homeostasis. Further investigations in larger cohorts are warranted to confirm and expand these findings.
format Online
Article
Text
id pubmed-8747176
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87471762022-01-11 A Synbiotic Formulation Comprising Bacillus subtilis DSM 32315 and L-Alanyl-L-Glutamine Improves Intestinal Butyrate Levels and Lipid Metabolism in Healthy Humans tom Dieck, Heike Schön, Christiane Wagner, Tanja Pankoke, Helga Carola Fluegel, Monika Speckmann, Bodo Nutrients Article The gut microbiota is a crucial modulator of health effects elicited by food components, with SCFA (short chain fatty acids), especially butyrate, acting as important mediators thereof. We therefore developed a nutritional synbiotic composition targeted at shifting microbiome composition and activity towards butyrate production. An intestinal screening model was applied to identify probiotic Bacillus strains plus various amino acids and peptides with suitable effects on microbial butyrate producers and levels. A pilot study was performed to test if the synbiotic formulation could improve fecal butyrate levels in healthy humans. A combination of Bacillus subtilis DSM (Number of German Collection of Microorganisms and Cell Cultures) 32315 plus L-alanyl-L-glutamine resulted in distinctly increased levels of butyrate and butyrate-producing taxa (Clostridium group XIVa, e.g., Faecalibacterium prausnitzii), both in vitro and in humans. Moreover, circulating lipid parameters (LDL-, and total cholesterol and LDL/HDL cholesterol ratio) were significantly decreased and further metabolic effects such as glucose-modulation were observed. Fasting levels of PYY (Peptide YY) and GLP-1 (Glucagon-like Peptide 1) were significantly reduced. In conclusion, our study indicates that this synbiotic composition may provide an effective and safe tool for stimulation of intestinal butyrate production with effects on e.g., lipid and glucose homeostasis. Further investigations in larger cohorts are warranted to confirm and expand these findings. MDPI 2021-12-29 /pmc/articles/PMC8747176/ /pubmed/35011015 http://dx.doi.org/10.3390/nu14010143 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
tom Dieck, Heike
Schön, Christiane
Wagner, Tanja
Pankoke, Helga Carola
Fluegel, Monika
Speckmann, Bodo
A Synbiotic Formulation Comprising Bacillus subtilis DSM 32315 and L-Alanyl-L-Glutamine Improves Intestinal Butyrate Levels and Lipid Metabolism in Healthy Humans
title A Synbiotic Formulation Comprising Bacillus subtilis DSM 32315 and L-Alanyl-L-Glutamine Improves Intestinal Butyrate Levels and Lipid Metabolism in Healthy Humans
title_full A Synbiotic Formulation Comprising Bacillus subtilis DSM 32315 and L-Alanyl-L-Glutamine Improves Intestinal Butyrate Levels and Lipid Metabolism in Healthy Humans
title_fullStr A Synbiotic Formulation Comprising Bacillus subtilis DSM 32315 and L-Alanyl-L-Glutamine Improves Intestinal Butyrate Levels and Lipid Metabolism in Healthy Humans
title_full_unstemmed A Synbiotic Formulation Comprising Bacillus subtilis DSM 32315 and L-Alanyl-L-Glutamine Improves Intestinal Butyrate Levels and Lipid Metabolism in Healthy Humans
title_short A Synbiotic Formulation Comprising Bacillus subtilis DSM 32315 and L-Alanyl-L-Glutamine Improves Intestinal Butyrate Levels and Lipid Metabolism in Healthy Humans
title_sort synbiotic formulation comprising bacillus subtilis dsm 32315 and l-alanyl-l-glutamine improves intestinal butyrate levels and lipid metabolism in healthy humans
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747176/
https://www.ncbi.nlm.nih.gov/pubmed/35011015
http://dx.doi.org/10.3390/nu14010143
work_keys_str_mv AT tomdieckheike asynbioticformulationcomprisingbacillussubtilisdsm32315andlalanyllglutamineimprovesintestinalbutyratelevelsandlipidmetabolisminhealthyhumans
AT schonchristiane asynbioticformulationcomprisingbacillussubtilisdsm32315andlalanyllglutamineimprovesintestinalbutyratelevelsandlipidmetabolisminhealthyhumans
AT wagnertanja asynbioticformulationcomprisingbacillussubtilisdsm32315andlalanyllglutamineimprovesintestinalbutyratelevelsandlipidmetabolisminhealthyhumans
AT pankokehelgacarola asynbioticformulationcomprisingbacillussubtilisdsm32315andlalanyllglutamineimprovesintestinalbutyratelevelsandlipidmetabolisminhealthyhumans
AT fluegelmonika asynbioticformulationcomprisingbacillussubtilisdsm32315andlalanyllglutamineimprovesintestinalbutyratelevelsandlipidmetabolisminhealthyhumans
AT speckmannbodo asynbioticformulationcomprisingbacillussubtilisdsm32315andlalanyllglutamineimprovesintestinalbutyratelevelsandlipidmetabolisminhealthyhumans
AT tomdieckheike synbioticformulationcomprisingbacillussubtilisdsm32315andlalanyllglutamineimprovesintestinalbutyratelevelsandlipidmetabolisminhealthyhumans
AT schonchristiane synbioticformulationcomprisingbacillussubtilisdsm32315andlalanyllglutamineimprovesintestinalbutyratelevelsandlipidmetabolisminhealthyhumans
AT wagnertanja synbioticformulationcomprisingbacillussubtilisdsm32315andlalanyllglutamineimprovesintestinalbutyratelevelsandlipidmetabolisminhealthyhumans
AT pankokehelgacarola synbioticformulationcomprisingbacillussubtilisdsm32315andlalanyllglutamineimprovesintestinalbutyratelevelsandlipidmetabolisminhealthyhumans
AT fluegelmonika synbioticformulationcomprisingbacillussubtilisdsm32315andlalanyllglutamineimprovesintestinalbutyratelevelsandlipidmetabolisminhealthyhumans
AT speckmannbodo synbioticformulationcomprisingbacillussubtilisdsm32315andlalanyllglutamineimprovesintestinalbutyratelevelsandlipidmetabolisminhealthyhumans